Replies to post #225452 on Biotech Values

[biotech jim]

This appears to be a very interesting dual acting agonist combination. I would like to see the relative potencies and data.

Preclinical evidence suggests high efficacy, when combining the gut-derived hormone GLP-1 with FGF21.

I could not find any USPTO filings using either agonist names along with 'Yuhan Corporation' in a quick look.